Trial Profile

Phase 1/2a study of sintilimab in combination with RC108 in Chinese patients with advanced solid tumors

Status: Planning

Phase of Trial: Phase I/II

Latest Information Update: 30 Jun 2023

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs RC 108 (Primary) ; Sintilimab (Primary)
Indications Solid tumours
Focus Adverse reactions; Therapeutic Use

Most Recent Events

30 Jun 2023 New trial record
26 Jun 2023 According to an Innovent Biologics media release, the company entered into a clinical trial collaboration and supply agreement with RemeGen Co., Ltd. Innovent will provide clinical drug supplies of TYVYT (sintilimab injection) during the clinical trial collaboration and RemeGen will conduct the studies.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com